CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today reported its consolidated financial results for the first quarter ended March 31, 2009 and company highlights. “This past quarter has been very productive, as we have executed across all dimensions of our company’s key value drivers – scientific leadership, clinical pipeline, intellectual property, and business development,” said John Maraganore, Ph.D., Chief Executive Officer of Alnylam. “While there’s more to do in our efforts, we view the opportunity for RNAi therapeutics as a potential new class of innovative medicines as stronger than ever based on the continued scientific and clinical progress led by Alnylam. We also continue to value the strength of our existing partnerships where there is a shared commitment to advancement of RNAi therapeutics, and we look forward to additional alliances we expect to add this year.”
